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ABSTRACT
Aim: It was the aim of the study to identify commonly deregulated miRNAs in oral cancer patients by
performing a meta-analysis of previously published miRNA expression profiles in cancer and matched
normal non-cancerous tissue in such patients.
Material and methods: Meta-analysis included seven independent studies analyzed by a vote-count-
ing method followed by bioinformatic enrichment analysis.
Results: Amongst seven independent studies included in the meta-analysis, 20 miRNAs were found to
be deregulated in oral cancer when compared with non-cancerous tissue. Eleven miRNAs were consist-
ently up-regulated in three or more studies (miR-21-5p, miR-31-5p, miR-135b-5p, miR-31-3p, miR-93-5p,
miR-34b-5p, miR-424-5p, miR-18a-5p, miR-455-3p, miR-450a-5p, miR-21-3p), and nine were down-regu-
lated (miR-139-5p, miR-30a-3p, miR-376c-3p, miR-885-5p, miR-375, miR-486-5p, miR-411-5p,
miR-133a-3p, miR-30a-5p). The meta-signature of identified miRNAs was functionally characterized by
KEGG enrichment analysis. Twenty-four KEGG pathways were significantly enriched, and TGF-beta sig-
naling was the most enriched signaling pathway. The highest number of meta-signature miRNAs was
involved in the sphingolipid signaling pathway. Natural killer cell-mediated cytotoxicity was the path-
way with most genes regulated by identified miRNAs. The rest of the enriched pathways in our miRNA
list describe different malignancies and signaling.
Conclusions: The identified miRNA meta-signature might be considered as a potential battery of bio-
markers when distinguishing oral cancer tissue from normal, non-cancerous tissue. Further mechanistic
studies are warranted in order to confirm and fully elucidate the role of deregulated miRNAs in oral
cancer.
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Introduction
Oral cancer is the most common type of head and neck
cancers, characterized by high mortality rates, low long-term
survival, and an increasing incidence among younger people
(1). As the complexity of oral cancer is still challenging con-
temporary medicine, further molecular characterization of
this cancer type is required. Identification of novel accurate
molecular biomarkers will facilitate early detection and con-
firmation of the oral cancer diagnosis at the molecular
level.
MicroRNA (miRNA) is a class of small non-coding RNA mol-
ecules which act as negative regulators of target gene
expression at the post-transcriptional level (2). MicroRNAs
induce gene silencing by binding to the 30 untranslated
region (30-UTR) of the target mRNA, which leads to either
mRNA degradation or translational repression (2). Almost all
key cellular processes, such as proliferation, development,
differentiation, and apoptosis, are regulated by miRNAs (2).
Therefore, it is not surprising that altered expression of par-
ticular miRNAs has been associated with occurrence of can-
cer, including oral cancer (3,4).
Identification of deregulated miRNAs in oral cancer is
important in the search for new sensitive molecular bio-
markers with diagnostic, predictive, and prognostic value
(3–5). Nowadays, the development of high-throughput tech-
nologies has enabled the identification of differentially
expressed miRNAs between cancer and non-cancerous tissue
samples on a large scale. However, the technologies used in
different studies are diverse, and the obtained results are not
entirely consistent. Therefore, our aim was to identify com-
monly deregulated miRNAs in oral cancer and characterize
their biological meaning by performing a comprehensive
meta-analysis of previously published miRNA expression
profiling studies, followed by bioinformatic enrichment
analysis.
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Material and methods
Search strategy and study inclusion/exclusion criteria
Literature searching (PubMed) was carried out by using dif-
ferent combinations of keywords: miRNA, microRNA, miR,
profile, profiling, signature, oral, cancer, tumour, tumor, car-
cinoma, squamous cell carcinoma. A last search was done on
31 January 2017. The meta-analysis was conducted to review
published studies that compared the miRNA expression pro-
files in oral cancer tissues with those in normal, matched oral
tissues. Therefore, we did not include miRNA expression data
from public databases such as TCGA (The Cancer Genome
Atlas) and GEO (Gene Expression Omnibus). The following
inclusion criteria were considered: (1) original articles pub-
lished in English with full text available; (2) miRNA expression
profiling in oral cancer specimens and matched non-cancer-
ous counterparts of the same patients; (3) studies with
reported lists of differentially expressed miRNAs and cut-off
criteria. Papers in other languages, review articles, studies
conducted on cell lines, analyzed expression of candidate
miRNAs, oral cancer tissue and healthy tissue collected from
different individuals, studies where different patient’s bio-
logical samples (such as blood, saliva, or serum) were used
were excluded from further analysis. Data provided in the
article’s supplementary material were also taken into consid-
eration. Studies with no reported lists of differentially
expressed miRNAs, or data that had only been shown on the
heatmap, where further information could not be obtained,
were excluded from the meta-analysis as well.
Meta-analysis of commonly deregulated miRNAs in oral
cancer
From studies included in the meta-analysis, lists of differen-
tially expressed miRNAs and their regulated directions in oral
cancer were collected. Annotations of differentially expressed
miRNAs in the different studies were harmonized according
to the miRBase database (www.mirbase.org) (release 21 June
2014). If the miRNA strand was not reported, dominant or
more abundant forms from the miRBase were used if applic-
able (6).
Meta-analysis was performed by means of a vote-counting
method, which considers the total number of studies reporting
consistently differentially expressed miRNAs (7,8). Fold change
was not reported in all included studies. Therefore, this criter-
ion was excluded in the miRNA meta-signature identification
by vote-counting strategy. Seven studies were analyzed, and
miRNAs reported as differentially expressed in at least three or
more studies were considered as commonly deregulated.
The analyses were performed using R programming lan-
guage and software environment for statistical computing
and graphics. R scripts are available in the Supplement
material S1 (available online).
Bioinformatic analysis
In order to access regulatory roles and identify molecular
pathways controlled by commonly deregulated miRNAs in
oral cancer, online open software DIANA-miRPath v3.0 (www.
microrna.gr/miRPathv3) was used (9). The algorithm microT
CDS v5.0 was used as prediction algorithm of miRNA–gene
interactions. DIANA-miRPath v3.0 uses meta-analysis statistics
for the assessment of combined miRNA action. The meta-
analysis algorithm enables the identification of pathways
controlled by multiple miRNAs by examining each miRNA
individually and subsequently combining the result probabil-
ities and test statistics (9). Functional analysis of commonly
deregulated miRNAs was done for Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways and Gene Ontology
(GO) biological process terms (9). Results were merged into
pathway and category union for KEGG and GO analysis,
depicting 1–the probability that the examined functional cat-
egory is significantly enriched with gene targets of at least
one selected miRNA. For the enrichment analysis method,
unbiased empirical distributions (10) with a microT threshold
of 0.7 and false discovery rate (FDR) correction were used.
Molecular pathways were considered significantly enriched
when p< 0.05. Heatmaps of significantly enriched pathways
were constructed using the DIANA-miRPath v3.0 tool (9).
Results
Overview of the studies included in the meta-analysis
By searching the PubMed database using different combina-
tions of the previously mentioned keywords, avoiding dupli-
cations and review papers, and after careful consideration of
all collected studies, seven studies met all inclusion criteria
and were considered for further analysis (11–17). Details of
the studies included in the meta-analysis are presented in
Table 1. For the identification of deregulated miRNAs in oral
cancer and matched normal tissue, different platforms and
cut-off values were utilized (Table 1). From studies which met
the required inclusion criteria, lists of differentially expressed
miRNAs were collected (Supplementary material S2, available
online). A total of 184 oral cancer samples and 162 matched
adjacent normal tissue samples were analyzed. Altogether in
the studies, 215 distinct miRNAs were identified to be
reported as differentially expressed, after harmonization of
annotations. In the list of all identified miRNAs, 93 miRNAs
showed up-regulation in studies where identified, 111
miRNAs showed down-regulation, and 11 miRNAs showed
inconsistent regulation (Supplementary material S3, available
online).
MicroRNA meta-signature of oral cancer
After harmonization of annotations, miRNAs found to be
deregulated in at least three studies were considered as
commonly deregulated (Table 2). Among 20 commonly
deregulated miRNAs in oral cancer compared to matched non-
cancerous tissue, 11 were consistently up-regulated (miR-21-5p,
miR-31-5p, miR-135b-5p, miR-31-3p, miR-93-5p, miR-34b-5p,
miR-424-5p, miR-18a-5p, miR-455-3p, miR-450a-5p, miR-21-3p),
while nine were consistently down-regulated (miR-139-5p,
miR-30a-3p, miR-376c-3p, miR-885-5p, miR-375, miR-486-5p,
miR-411-5p, miR-133a-3p, miR-30a-5p). Throughout our study
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miR-223-3p, miR-203-3p, and miR-17-5p also passed the iden-
tification threshold, but showed different regulated directions
(Table 2). Therefore, for further analysis only miRNAs with
consistent regulated direction in oral cancer were considered
in the oral cancer meta-signature, while miR-223-3p, miR-
203-3p, and miR-17-5p were excluded due to expression
inconsistencies. Two of the most commonly up-regulated
miRNAs in oral cancer, identified in five out of seven studies,
were miR-21-5p and miR-31-5p. In a signature of consistently
reported up-regulated miRNAs, miR-31-3p and miR-135b-5p
were reported in four studies. Four studies also showed
down-regulation of miR-139-5p, miR-30a-3p, and miR-376c-3p
in oral cancer when compared with non-cancerous tissue.
The rest of the deregulated miRNAs, included in the oral can-
cer meta-signature, were reported in three studies out of
seven (Table 2).
Table 1. Details of the included studies.
Study (reference)
Number of
tissue samples
(cases/control)a
Differentially expressed miRNA
Cut-off criteria Platform CountryTotal Up-regulated Down-regulated
Ganci et al., 2016 (11) 76 (38/38) 78 59 19 FDR <0.06
p< 0.01
FC >1
Agilent platform Human
miRNA microarray (V2)
Italy, Europe
Manikandan et al., 2016 (12) 58 (29/29) 39 15 24 SD >1
FC >1
p< 0.05
miRCURY LNATM
microRNA array
(Exiqon)
India, Asia
Shiah et al., 2014 (13) 80 (40/40) 84 32 52 FC >2
p< 0.05
Human v2 microRNA
expression BeadChips
(Illumina)
Taiwan, Asia
Soga et al., 2013 (14) 36 (29/7) 23 12 11 FC >4 TaqMan Low Density
Array (Human
microRNA Panel v2.0)
Japan, Asia
Shi et al., 2015 (15) 4 (2/2) 38 31 7 FC >2 RNA Seq (Illumina HiSeq
2000)
China, Asia
Fukumoto et al., 2015 (16) 72 (36/36) 42 NR 42 p< 0.05 TaqMan Low Density
Array (Human
microRNA Panel v2.0)
Japan, Asia
Chen et al., 2017 (17) 20 (10/10) 12 7 5 p< 0.05 p< 0.01 TaqMan Low Density
Array (TLDA v1.0)
USA
aOral cancer tissue specimens/matched adjacent non-cancerous tissue from the same individual.
FC: fold change; FDR: false discovery rate; NR: not reported; SD: standard deviation.
Table 2. List of commonly deregulated miRNAs in oral cancer compared with matched non-cancerous tissue among different studies.
Deregulated
miRNAs
Common:
studies (n)
Up-regulated:
studies (n)
Down-regulated:
studies (n) Present in study Samples (n)a
miR-21-5p 5 5 0 Ganci et al., 2016; Soga et al., 2013; Shi et al., 2015; Chen et al.,
2017; Manikandan et al., 2016
176
miR-31-5p 5 5 0 Ganci et al., 2016; Soga et al., 2013; Chen et al., 2017;
Manikandan et al., 2016; Shiah et al., 2014
252
miR-139-5p 4 0 4 Soga et al., 2013; Fukumoto et al., 2015; Chen et al., 2017;
Shiah et al., 2014
208
miR-30a-3p 4 0 4 Soga et al., 2013; Shi et al., 2015; Fukumoto et al., 2015; Shiah
et al., 2014
192
miR-376c-3p 4 0 4 Ganci et al., 2016; Soga et al., 2013; Fukumoto et al., 2015;
Shiah et al., 2014
264
miR-223-3pb 4 3 1 Ganci et al., 2016; Soga et al., 2013; Chen et al., 2017;
Manikandan et al., 2016
190
miR-135b-5p 4 4 0 Ganci et al., 2016; Soga et al., 2013; Shi et al., 2015; Shiah
et al., 2014
196
miR-31-3p 4 4 0 Ganci et al., 2016; Soga et al., 2013; Manikandan et al., 2016;
Shiah et al., 2014
250
miR-885-5p 3 0 3 Shi et al., 2015; Fukumoto et al., 2015; Shiah et al., 2014 156
miR-375 3 0 3 Shi et al., 2015; Fukumoto et al., 2015; Shiah et al., 2014 156
miR-486-5p 3 0 3 Soga et al., 2013; Chen et al., 2017; Shiah et al., 2014 140
miR-411-5p 3 0 3 Soga et al., 2013; Fukumoto et al., 2015; Shiah et al., 2014 188
miR-203-3pb 3 2 1 Soga et al., 2013; Shi et al., 2015; Manikandan et al., 2016 98
miR-133a-3p 3 0 3 Ganci et al., 2016; Soga et al., 2013; Shiah et al., 2014 192
miR-30a-5p 3 0 3 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
miR-17-5pb 3 2 1 Ganci et al., 2016; Shi et al., 2015; Manikandan et al., 2016 138
miR-93-5p 3 3 0 Ganci et al., 2016; Soga et al., 2013; Shi et al., 2015 116
miR-34b-5p 3 3 0 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
miR-424-5p 3 3 0 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
miR-18a-5p 3 3 0 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
miR-455-3p 3 3 0 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
miR-450a-5p 3 3 0 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
miR-21-3p 3 3 0 Ganci et al., 2016; Shi et al., 2015; Shiah et al., 2014 160
aNumber of tissue samples tested across the studies.
bDue to inconsistencies in expression among studies, miRNAs were not further considered as commonly deregulated in oral cancer compared with matched
non-cancerous tissue.
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Functional annotation of commonly deregulated
miRNAs in oral cancer
For further functional characterization the identified miRNA
meta-signature was the subject of GO and KEGG enrichment
analysis. We have noticed that GO enrichment using
unbiased empirical distributions approach gave insufficient
enrichment results, in contrast to the Fisher exact test (data
not shown). However, it was recently pointed out that
miRNA enrichment analysis using the Fisher test introduces
bias (10), so we decided to proceed with the knowledge
acquired by unbiased empirical distributions method.
Twenty-four KEGG pathways were significantly enriched in
the oral cancer miRNA meta-signature (Table 3, Figure 1).
Pathways enriched in our miRNA list are coupled to different
malignancies. Also, there was a plethora of signaling path-
ways. TGF-beta was the most enriched signaling pathway,
while the highest number of meta-signature miRNAs regulate
genes involved in the sphingolipid signaling pathway. The
pathway with the highest number of genes regulated by
identified miRNAs was the natural killer cell (NK)-mediated
cytotoxicity (Table 3, Figure 1).
Discussion
The fast development of high-throughput technologies has
enabled easier identification of possible molecular biomarkers
for different pathologies, including cancer. However, due to
differently used platforms, sample sizes, data analysis, and
interpretation, a high level of inconsistency among studies
exists (11–17). Therefore, the need for integration of results
from different studies through meta-analyses is justified.
Results of deregulated miRNAs reported in the studies
included in the current meta-analysis are inconsistent.
Numerous factors can contribute to this inconsistency, for
instance, small effect sizes, sample preparation and storage,
clinical characteristics of the patients, normalization of
obtained data and data analysis, and different cut-off criteria
for identification of differentially expressed miRNAs. These
noticed inconsistencies among studies might emerge from
differences in used platforms and types and numbers of
probes as well. Even intra-tumor heterogeneity of miRNA
expression (18,19) as well as molecular changes related to
cancerogenesis in morphologically normal tissue (20) could
introduce the inconsistency.
Our results regarding mir-21, mir-31, mir-133, and mir-139
deregulation in oral cancer are in line with findings reported
in a recently published meta-analysis (21). Existing non-over-
lapping miRNAs between that and our study can be
explained with more rigorous criteria applied in the selection
process of our study. The finding of an up-regulation of
mir-21 was not a surprise, since mir-21 is considered as an
oncomir and therefore is highly expressed in various cancer
types (22). Mir-21 has been considered to be a potential bio-
marker for tongue cancer detection (23) and progression and
survival (24). Increased mir-21 expression is associated with
poor survival of patients with head and neck cancer accord-
ing to recently conducted meta-analysis (25). It has also been
shown that miR-21-3p is overexpressed in oral cancer and
that it plays an important role in metastasis (26). Likewise,
the up-regulation of mir-31 in oral cancer is probably a result
of epidermal growth factor receptor (EGFR) activation (27).
Increased expression of mir-31 was also noticed in early
stages of oral cancer with no detected metastasis (28). Up-
regulation of mir-31 was proposed as a suitable biomarker of
increased malignant transformation of oral, potentially malig-
nant disorders (29). Down-regulation of miR-133a-3p was
reported in oral cancer as well as in oral cancer cell lines
(30). Oral cancer proliferation and invasion can be suppressed
by miR-133a-3p over-expression and collagen type I alpha 1
chain gene (COL1A1) direct targeting (30). Decreased expres-
sion of miR-139-5p has been reported as a potential saliva
biomarker for tongue cancer detection (31).
The activity of other meta-signature miRNAs was also
examined in oral cancer. In a study investigating miRNA
expression in oral cancer patients with and without metasta-
sis, mir-135b was suggested to be a promising down-regu-
lated biomarker of oral cancer progression (32). It was found
that down-regulated miR-376c-3p suppresses the cancer
phenotype by targeting homeobox B7 (HOXB7) in oral cancer
tissue as well as in cell lines (33). In addition, in head and
neck cancer, down-regulated miR-376c-3p leads to runt-
related transcription factor 2 gene (RUNX2) deregulation and
is associated with lymph node metastasis (34). Poor progno-
sis of head and neck cancer patients was associated with up-
regulated expression of mir-93 (35) and mir-18a (25). Mir-34b
has been found to be one of the consistently up-regulated
miRNAs in head and neck cancer in a majority of studies as
well (36). A recent study reported that in oral cancer miR-
424-5p directly targets supressor of cytokine signaling gene
(SOCS2) and modulates STAT5 signaling, expression of matrix
metalloproteinase, cell migration, and invasion (37). It has
been reported that miR-455-3p up-regulation is controlled by
the TGF-beta pathway, consequently down-regulating
Table 3. List of KEGG pathways enriched in oral cancer miRNA meta-
signature.
KEGG pathway p valuea Genes (n) MiRNAs (n)
Acute myeloid leukemia 0.006443 3 2
TGF-beta signaling pathway 0.011516 4 1
Hepatitis C 0.013149 19 4
Proteoglycans in cancer 0.015179 28 2
Non-small cell lung cancer 0.016204 9 3
Estrogen signaling pathway 0.019171 18 3
Pancreatic cancer 0.022215 10 2
Cardiac muscle contraction 0.023825 2 1
Sphingolipid signaling pathway 0.02472 17 4
AMPK signaling pathway 0.026242 8 2
ErbB signaling pathway 0.026337 3 1
Natural killer cell-mediated cytotoxicity 0.028397 29 3
Neurotrophin signaling pathway 0.032315 12 1
mTOR signaling pathway 0.032902 10 3
Chronic myeloid leukemia 0.033489 9 2
Hippo signaling pathway 0.033673 5 1
FoxO signaling pathway 0.035991 18 2
cGMP-PKG signaling pathway 0.036768 3 1
Melanoma 0.03704 18 3
Jak-STAT signaling pathway 0.037747 14 2
Prolactin signaling pathway 0.040764 4 1
Glioma 0.042782 6 2
Chagas disease (American trypanosomiasis) 0.04822 6 1
Measles 0.049572 4 1
ap< 0.05 was considered as statistically significant.
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ubiquitin conjugating enzyme E2B gene (UBE2B), which
results in oral cancer proliferation (38).
Recent studies have emphasized the utility of mir-375 as a
biomarker for detection of tongue cancer (23), malignant
transformation of oral lesions (39), and late stages of oral
cancer (28). Mir-375 has been down-regulated in metastatic
oral cancer cell lines compared with less metastatic cells, and
mir-375 induced cell migration and invasion by direct target-
ing the platelet-derived growth factor-A (PDGF-A) (40).
Mir-375 mediates the trichostatin-A-induced radiosensitization
of tongue cancer (41), indicating a therapeutic potential of
mir-375. In addition, down-regulation of plasma circulating
mir-375 and miR-486-5p has been associated with oral cancer
recurrence (42). To the best of our knowledge, expression of
mir-30a has not been studied in oral cancer. However, it has
been reported that alcohol induces deregulation of mir-30a
by increasing its expression in head and neck cancer (43).
It is well established that aberrant regulation of the signal-
ing pathways is a prevalent theme in cancer. The most
enriched signaling pathway is that of TGF-beta. It is involved
Figure 1. Heatmap of KEGG pathways enriched in oral cancer miRNA meta-signature. The heatmap depicts the enrichment level of KEGG pathways in miRNAs com-
monly deregulated in oral cancer (microT CDS v5.0 was used for target prediction, p value threshold 0.05, microT threshold 0.7, and enrichment analysis method:
unbiased empirical distributions). Intensity of colors represents the log (p value).
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in the regulation of crucial cellular processes of importance
for cancerogenesis: cell growth, differentiation, apoptosis,
and angiogenesis (44). The dual role of TGF-beta has been
proposed in cancer formation—from protection from cancer
progression in the early stages, to cancer promotion in later
stages (44). Regarding enrichment analysis, the highest num-
ber of miRNAs regulate genes involved in the sphingolipid
signaling pathway. Ceramide, sphingosine-1-phosphate, and
their signaling cascade have been implicated in various
aspects of oncogenesis and cancer progression (45). The
main reason is that both lipids regulate the PI3K/AKT path-
way, which represses apoptosis and autophagy (45).
Sphingolipids also have an impact on cell cycle progression,
telomerase function, cell migration, and stem cell biology
(45). On the other hand, most of the genes regulated by
miRNAs in our analysis belonged to the natural killer cell
(NK)-mediated cytotoxicity. In vitro studies on human and
other mammal cells, as well as in vivo studies in rodents,
have suggested that NK cells target tumor cells (46).
However, it has been suggested that tumors release exo-
somes which inhibit IL-2-induced NK cell cytotoxicity (47). It
is known that exosomes contain miRNAs (48), which have
the potential to regulate processes involved in NK cell
homeostasis, survival, and turnover. As the cancerous and
healthy tissues were obtained from the same patients, differ-
entially expressed miRNAs might be involved in NK cytotox-
icity modulation if transmitted by exosomes from cancer cells
to NK cells via previously observed mechanisms (49).
When interpreting results obtained by the vote-counting
method, some considerations have to be taken into account,
keeping in mind different limitations and shortcomings (50).
However, the vote-counting method has been recommended
and is considered as a good alternative for identification of
consistent gene expression (7,8), as well as a reliable strategy
in searching for potential miRNA biomarkers in colorectal
(51) and lung cancer (52).
To sum up, results reported in the current study can be
helpful for more focused future confirmatory analysis of pre-
selected miRNAs expression in oral cancer patients. Further
validation and mechanistic studies of reported miRNA signa-
ture are highly warranted. It would also be interesting
to perform more in-depth analysis of identified miRNA meta-
signature in association with clinical data, such as patient sur-
vival, outcome, and metastasis.
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